

R&D Pipeline



Filed • Approved

antibody protein small molecule

As of Jun. 30, 2019

Area		Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
Nephrology		KRN321 Darbeopetin Alfa Injection	Long-Acting Erythropoiesis Stimulating Agent	Renal Anemia (on Dialysis)	Filed in CN	Kirin-Amgen	
				Renal Anemia	Filed in ID		
		KHK7580 Evocalcet Oral	Calcium Receptor Agonist	Hypercalcemia In Patients With Parathyroid Carcinoma or Primary Hyperparathyroidism	Filed in JP	Licensed from Mitsubishi Tanabe Pharma	
Immunology/Allergy		KHK4827 Brodalumab Injection	Anti-IL-17 Receptor A Fully Human Antibody	Psoriasis	Filed in KR Filed in SG Filed in MY Filed in CN	Kirin-Amgen	
Central Nervous System		KW-6002 Istradefylline Oral	Adenosine A _{2A} Receptor Antagonist	Parkinson's Disease	Filed in US	In-House	
Other		©KRN23 Burosumab Injection	Anti-FGF23 Fully Human Antibody	X-linked Hypophosphatemia (XLH)	Filed in TW	In-House	Human Antibody-Producing Technology Jointly Developed with Ultragenyx in US and EU
					Filed in CH		
					Filed in KW		
					Filed in SA		
					Filed in CN		
					Filed in HK		
		AMG531 Romiplostim Injection	Thrombopoietin Receptor Agonist	Aplastic Anemia Who Have Had an Inadequate Response to Conventional Therapy	Approved in JP	Kirin-Amgen	

Phase II, Phase III

Area		Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
Nephrology		©RTA 402 Bardoxolone Methyl Oral	Antioxidant Inflammation Modulator	Diabetic Kidney Disease	Phase III in JP	Licensed from Reata	
		KHK7580 Evocalcet Oral	Calcium Receptor Agonist	Secondary Hyperparathyroidism	Phase III in CN, KR, TW and HK	Licensed from Mitsubishi Tanabe Pharma	
		©KHK7791 Tenapanor Oral	NHE3 inhibitor	Hyperphosphatemia Under Maintenance Dialysis	Phase II in JP	Licensed from Ardelyx	
Oncology		©KHK2375 Entinostat Oral	HDAC Inhibitor	Breast Cancer	Phase II in JP	Licensed from Syndax	
		KW-0761 Mogamulizumab Injection	Anti-CCR4 Humanized Antibody	Adult T-cell Leukemia/Lymphoma	Phase II in US, EU and others	In-House	POTELLIGENT®
		KRN125 Pegfilgrastim Injection	Long-Acting Granulocyte Colony Stimulating Factor	Mobilization of Hematopoietic stem cell into Peripheral blood	Phase II in JP	Kirin-Amgen	
Immunology/Allergy		©KHK4083 Injection	Anti-OX40 Fully Human Antibody	Ulcerative Colitis Atopic Dermatitis	Phase II in US, EU and others Phase II in JP, US, CA and EU	In-House	POTELLIGENT® Human Antibody-Producing Technology
		KHK4827 Brodalumab Injection	Anti-IL-17 Receptor A Fully Human Antibody	Axial Spondyloarthritis (axSpA) Systemic Sclerosis	Phase III in JP, KR and TW Phase III in JP	Kirin-Amgen	
		©ASKP1240 Bleselumab Injection	Anti-CD40 Fully Human Antibody	Recurrence of Focal Segmental Glomerulosclerosis (FSGS) in <i>de</i> <i>novo</i> kidney transplant recipients	Phase II in US	In-House	Human Antibody-Producing Technology Jointly Developed with Astellas
		KW-0761 Mogamulizumab Injection	Anti-CCR4 Humanized Antibody	HTLV-1 associated myelopathy (HAM)	Phase III in JP	In-House	POTELLIGENT®
Central Nervous System		©KW-6356 Oral	Adenosine A _{2A} Receptor Antagonist	Parkinson's Disease	Phase II in JP	In-House	
Other		©KRN23 Burosumab Injection	Anti-FGF23 Fully Human Antibody	X-linked Hypophosphatemia (XLH) in adult patients	Phase III in US, CA, EU, JP and KR	In-House	Human Antibody-Producing Technology Jointly Developed with Ultragenyx in US and EU
				X-linked Hypophosphatemia (XLH) in pediatric patients	Phase III in US, CA, EU, AU, JP and KR		
				Tumor Induced Osteomalacia (TIO)/Epidermal Nevus Syndrome (ENS)	Phase II in US Phase II in JP and KR		
		AMG531 Romiplostim Injection	Thrombopoietin Receptor Agonist	Aplastic Anemia Who Have Had an Inadequate Response to Conventional Therapy Aplastic Anemia who were Previously Untreated with Immunosuppressive Therapy Idiopathic (Immune) Thrombocytopenic Purpura	Phase II / III in KR Phase II / III in JP, KR and TW Phase III in CN	Kirin-Amgen	

Updated since Mar. 31, 2019 (Area, Stage, Filed, Approved, etc.)
 New Molecular Entity

R&D Pipeline

antibody
 protein
 small molecule

Phase I

As of Jun. 30, 2019

Area		Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
Oncology		©KHK2455 Oral	IDO1 Inhibitor	Solid Tumor	Phase I in US	In-House	Combination with KW-0761
		KW-0761 Mogamulizumab Injection	Anti-CCR4 Humanized Antibody	Solid Tumor	Phase I / II in US	In-House	POTELLIGENT® Combination with Nivolumab (Jointly Developed with Bristol-Myers Squibb)
		©ME-401 Oral	PI3Kδ inhibitor	B-cell malignancies	Phase I in JP	Licensed from MEI Pharma	
Immunology/ Allergy		©KHK4083 Injection	Anti-OX40 Fully Human Antibody	Ulcerative Colitis	Phase I in JP	In-House	POTELLIGENT® Human Antibody-Producing Technology
		KHK4323 Injection		Atopic Dermatitis	Phase I in JP	In-House	
Central Nervous System		©KHK6640 Injection	Anti-Amyloid Beta Peptide Antibody	Alzheimer's Disease	Phase I in EU Phase I in JP	Licensed from Immunas Pharma	
Others		KW-3357 Antithrombin Gamma Injection	Recombinant Human Antithrombin	Disseminated Intravascular Coagulation, Congenital Antithrombin Deficiency	Phase I in EU	In-House	

 Updated since Mar. 31, 2019 (Area, Stage, Filed, Approved, etc.)
 © New Molecular Entity

Updated since Mar. 31, 2019 (Area, Stage, Filed, Approved, etc.)

Filed • Approved

Area		Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
Nephrology		KHK7580 Evocalcet Oral	Calcium Receptor Agonist	Hypercalcemia In Patients With Parathyroid Carcinoma or Primary Hyperparathyroidism	Filed in JP	Licensed from Mitsubishi Tanabe Pharma	
Immunology/ Allergy		KHK4827 Brodalumab Injection	Anti-IL-17 Receptor A Fully Human Antibody	Psoriasis	Filed in CN	Kirin-Amgen	
Others		©KRN23 Burosumab Injection	Anti-FGF23 Fully Human Antibody	X-linked Hypophosphatemia (XLH)	Filed in SA Filed in CN	In-House	Human Antibody-Producing Technology Jointly Developed with Ultragenyx in US and EU
				FGF23-Related Hypophosphatemic Rickets and Osteomalacia	Filed in HK		
					Filed in KR		
		AMG531 Romiplostim Injection	Thrombopoietin Receptor Agonist	Aplastic Anemia Who Have Had an Inadequate Response to Conventional Therapy	Approved in JP	Kirin-Amgen	

Phase II, Phase III

Area		Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
Nephrology		KHK7580 Evocalcet Oral	Calcium Receptor Agonist	Secondary Hyperparathyroidism	Phase III in CN, KR, TW and HK	Licensed from Mitsubishi Tanabe Pharma	
Oncology		KRN125 Pegfilgrastim Injection	Long-Acting Granulocyte Colony Stimulating Factor	Mobilization of Hematopoietic stem cell into Peripheral blood	Phase II in JP	Kirin-Amgen	
Immunology /Allergy		KHK4827 Brodalumab Injection	Anti-IL-17 Receptor A Fully Human Antibody	Systemic Sclerosis	Phase III in JP	Kirin-Amgen	
Others		AMG531 Romiplostim Injection	Thrombopoietin Receptor Agonist	Aplastic Anemia Who Were Previously Untreated with Immunosuppressive Therapy	Phase II / III in JP, KR and TW	Kirin-Amgen	

Phase I

Area		Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
Oncology		©ME-401 Oral	PI3Kδ inhibitor	B-cell malignancies	Phase I in JP	Licensed from MEI Pharma	

Terminated

Area		Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
Oncology		©KHK2823 Injection	Anti-CD123 Fully Human Antibody	Cancer	Phase I in UK	In-House	POTELLIGENT® Human Antibody-Producing Technology